SCHEMBL6028207

SCHEMBL6028207

COc1ccc(-c2cnc(SCC(=O)NC(Cc3ccc(Cl)c(Cl)c3)C3CCCNC3)nc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.39
PDPK1 O15530 1/20 0.38
RPS6KB1 P23443 1/20 0.38
AKT1 P31749 2/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38
TP53 P04637 2/20 0.37
CDK2 P24941 1/20 0.37
POLB P06746 1/20 0.37
SSTR3 P32745 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
IKBKB O14920 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
JAK3 P52333 1/20 0.36
LMNA P02545 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7819214 0.95 AKT1 (0.42) AKT1GRIN1GRIN2BTP53SSTR3
Hydrochloric Acid SCHEMBL7830259 0.95 AKT1 (0.41) AKT1GRIN1GRIN2BTP53SSTR3
SCHEMBL6028748 0.93 CHEK1 (0.39) CHEK1PDPK1RPS6KB1GRIN1GRIN2B
SCHEMBL6029095 0.93 CHEK1 (0.39) CHEK1PDPK1RPS6KB1GRIN1GRIN2B
SCHEMBL6029187 0.91 MAPT (0.38) CHEK1PDPK1RPS6KB1GRIN1GRIN2B
SCHEMBL6028227 0.91 LMNA (0.41) PDPK1RPS6KB1TP53POLBRAB9A
SCHEMBL6028983 0.90 CDK2 (0.38) CHEK1PDPK1RPS6KB1AKT1GRIN2B
SCHEMBL6028842 0.89 CHEK1 (0.39) CHEK1PDPK1RPS6KB1GRIN1GRIN2B
SCHEMBL6029151 0.88 CHEK1 (0.39) CHEK1PDPK1RPS6KB1AKT1GRIN1
SCHEMBL6030080 0.87 MCHR1 (0.44) TP53POLBLMNAMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6984643-B2 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists ROCHE PALO ALTO LLC (US) 2006-01-10 US disclosed
EP-1521582-A1 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-04-13 EP disclosed
US-20040014775-A1 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists ROCHE PALO ALTO LLC 2004-01-22 US disclosed
WO-2004004731-A1 2, 5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS IX F. HOFFMANN-LA ROCHE AG (CH) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014775-A1 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists CCR3, CCR1, CCRL2 CHEK1 531/4885PDPK1 2192/4885RPS6KB1 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.